Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)

Next Previous
Search
Trial Profile

Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albumins (Primary) ; Plasma (Primary) ; Ruxolitinib (Primary)
  • Indications COVID 2019 infections; Cytokine release syndrome; Respiratory insufficiency
  • Focus Pharmacodynamics

    • Most Recent Events

    • 30 Nov 2021 Primary end-point has been updated and ORR has been replaced by C-reactive Protein (CRP) Levels and Cytokine Levels, thus changing the trial focus from TU to AR.
    • 24 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2020 Planned End Date changed from 30 Apr 2021 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top